Minimal/Measurable Residual Disease - The Bloodline with Blood Cancer United Podcast

With so many new advances in acute lymphoblastic leukemia (ALL), understanding today’s treatment landscape can give patients a clearer, more hopeful outlook.

In this episode, we speak with Marlise Luskin, MD of the Dana-Farber Cancer Institute, about what adults should know when facing a diagnosis of acute lymphoblastic leukemia. Dr. Luskin helps listeners understand how ALL develops, how subtypes are identified, and why genetics play an important role in guiding treatment. She discusses current therapies including chemotherapy, targeted agents and immunotherapies including CAR T-cell therapy, as well as how care teams monitor progress and manage side effects. While ALL is a complex disease, patients and caregivers will hear clear explanations, practical information, and meaningful reasons to feel hopeful about the advances shaping ALL care today.

Mentioned on this episode: 

Additional Blood Cancer United Support Resources: 

Episode supported by Syndax Pharmaceuticals Inc.

The post Acute Lymphoblastic Leukemia (ALL): The New Tools Shaping Tomorrow first appeared on The Bloodline with Blood Cancer United Podcast.

MRD (minimal/measurable residual disease) testing is changing the way doctors understand and monitor blood cancers.  In this episode, we talk with Dr. John Burke of the Rocky Mountain Cancer Center about how MRD testing works, what the results mean to patients and their care teams, and how ongoing clinical research is helping shape more personalized and hopeful approaches to treatment. 

Mentioned on this episode: 

Additional LLS Support Resources: 

Supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.

The post MRD Explained: What it Means for You and Your Care first appeared on The Bloodline with Blood Cancer United Podcast.

Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.

In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.   

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Adaptive Biotechnologies

The post Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer first appeared on The Bloodline with Blood Cancer United Podcast.

Have you ever wondered how doctors determine the treatment for a blood cancer patient? In this episode, we’re speaking with Dr. Eric Severson of Labcorp Oncology and Dr. John DiPersio of Washington University in St. Louis, MO, about genomics testing, what it is, and how it benefits blood cancer patients. You will learn about the crucial collaboration between pathologists and oncologists to make sure patients are getting the most accurate diagnosis and best possible treatments for their particular blood cancers.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Labcorp Oncology.

The post The Revolution of Genomics: How Testing Leads to Individualized Treatment first appeared on The Bloodline with Blood Cancer United Podcast.

Join us as we speak to Dr. Lori Muffly and Dr. Matthew Frank from Stanford Medicine in Stanford, CA, about the recent advancements in testing for Minimal/Measurable Residual Disease (MRD). In this episode, we delve into what MRD is, which blood cancers testing is currently used on, and how we can utilize it to more accurately monitor patients and customize treatment. The doctors also share exciting possibilities on how MRD and other testing can benefit patients in the future.

Mentioned

• Minimal/Measurable Residual Disease
• A Medication Resource for Blood Cancer Patients
• Minimal/Measurable Residual Disease Chart 
• Stanford Medicine Research
• CAPP-Seq test – Ash Alizadeh
• Acute Lymphoblastic Leukemia (ALL)  

Additional LLS Support Resources:

• Information Specialists 
• Free telephone/web patient programs 
• Free booklets 
• Financial support 
• Online chats 
• Caregiver support 
• LLS Community 
• Support groups 
• Patti Robinson Kaufmann First Connection Program Free Nutrition Consultations

Support for this episode provided by Genentech, Inc. and Biogen.

The post Exploring Minimal/Measurable Residual Disease (MRD) first appeared on The Bloodline with Blood Cancer United Podcast.